Cheap 2 mg and 4 mg Zanaflex still add up to 36 mg in a day

Cheap Zanaflex still stops the day at 36 mg

Cheap Zanaflex still stops the day at 36 mg. The US label stops the stack at 36 mg in twenty-four hours. That is not one swallow. Titration starts at 2 mg or 4 mg. Single doses that climb past 8-16 mg raise hypotension before they raise tone relief. The card files that ceiling. It does not ship tablets.

A 4 mg tablet and a 4 mg capsule both spend the same 36 mg day

A 4 mg tablet and a 4 mg capsule both add 4 mg toward the 36 mg ceiling. They are not interchangeable on food effect, so a form switch still needs retitration. The daily stop does not reset because the bottle says capsule. The stack rule stays on this card. Neither form is for sale here.

Cheap 2 mg and 4 mg bands that stay under 36 mg

PMX tizanidine card quotes, August 2026. Walmart / Walgreens / Sam's Club / Albertsons. 2 mg or 4 mg x 30. Snapshot. Script required. Not a cart.

Walmart, Walgreens, Sam's Club, and Albertsons already post coupon or warehouse numbers for 2 mg or 4 mg x 30. Figures below are August 2026 snapshots from GoodRx and SingleCare. Your ZIP moves the dollar. Confirm at the counter. A script is required.

Why 36 mg is the Zanaflex day, not a starting swallow

Spasticity is one of those problems that looks like 'stiffness' on rounds but costs people sleep, transfers, and skin integrity when it goes untreated. In upper motor neuron syndromes-multiple sclerosis, spinal cord injury, sometimes stroke-you are trying to reduce velocity-dependent tone without trading it for global weakness that makes function worse.

Oral options you actually reach for include baclofen, benzodiazepines, and tizanidine. Baclofen is GABAergic and can feel like weakness at effective doses. Benzodiazepines sedate broadly. Tizanidine sits in the middle: meaningful Ashworth-scale improvement at doses many patients tolerate, with sedation and blood pressure drops as the usual ceiling.

Tizanidine (Zanaflex) is FDA-approved specifically for spasticity from MS or spinal cord injury. It is not a first-line agent for acute low back spasm in otherwise neurologically intact adults-that off-label use happens, but the evidence and risk profile you are teaching today come from chronic spasticity populations.

Card note: the drug behaves like a spinal clonidine cousin: alpha-2 agonism reduces release of excitatory amino acids from interneurons, which quiets polysynaptic stretch reflexes. Patients often notice effect within one to two hours of a dose, which helps you time dosing around therapy or sleep.

Two practical facts separate competent prescribers from dangerous ones. First, elimination runs through CYP1A2, so fluvoxamine and ciprofloxacin are contraindicated-not 'monitor closely,' contraindicated. Second, capsules and tablets are not milligram-for-milligram interchangeable because food hits the capsule formulation much harder. FDA labeling tells you to retitrate when switching forms.

On inpatient services, tizanidine appears on reconciliation lists next to antihypertensives, opioids, and sleep aids. Each addition raises syncope risk. Falls in MS and SCI already carry outsized morbidity; orthostatic lightheadedness from a drug interaction is preventable if you treat CYP1A2 like a hard contraindication pathway.

When you compare tizanidine with baclofen in clinic, frame the choice as adverse-effect trade-offs, not winner-take-all efficacy. Some patients do better on tizanidine because hypotension is easier to manage than the weakness baclofen causes at antispastic doses. Others need intrathecal baclofen when oral agents fail-tizanidine is not a substitute for that escalation.

Rehabilitation teams measure success in transfers, dressing, and sleep hours-not Ashworth points alone. Ask whether morning stiffness or nocturnal leg spasms is the dominant complaint before you map doses across the day. A patient who only needs relief at night may never require daytime tizanidine at all.

Insurance formularies swap capsule and tablet without telling you. When prior authorization renews, confirm dosage form on the bottle matches what you titrated. A 'same mg' switch after a generic change is one of the most common reasons for sudden sedation or loss of effect.

Acute low back pain scripts for cyclobenzaprine or methocarbamol are a different conversation. Tizanidine's labeled home is chronic spasticity from MS and SCI. Using it for generic back spasm exposes patients to hypotension without evidence that beats simpler options.

Morning MS clinic: one patient stable on tizanidine for years, one just got cipro from urgent care, one whose pharmacy swapped capsule for tablet and says it stopped working. Those three cases are the bulk of tizanidine safety-interactions, formulation, titration-not exotic pharmacogenetics.

Whoever refills tizanidine inherits CYP1A2 rules and formulation documentation. Continuity gaps become ED syncope visits, not missed Ashworth scores.

Consider the patient with T6 SCI on tizanidine 4 mg TID who presents lightheaded after starting fluvoxamine for OCD-this is not a neurology mystery. Stop the offending inhibitor, support blood pressure, and re-titrate tizanidine from 2 mg when stable. The mechanism is predictable CYP1A2 blockade raising exposure several-fold, not disease progression.

Card note: formulary committees love tizanidine because it is generic and non-controlled, but that accessibility increases interaction burden-every prescriber in the chain must know the contraindications. Build a dot phrase or order-set alert for CYP1A2 pairs in EMRs where spasticity populations concentrate.

Nighttime dosing strategy deserves explicit teaching: many SCI patients prefer 4-6 mg at bedtime only, achieving sleep and spasm relief without daytime sedation that interferes with work or driving. Daytime doses are optional based on functional goals, not mandatory because the label allows TID.

Card note: when you pre-round on rehabilitation floors, tizanidine appears on the board next to baclofen and diazepam with no distinction-yet the pharmacology could not be more different from a monitoring standpoint. Baclofen withdrawal can seize; tizanidine withdrawal can hypertend; both sedate; only tizanidine carries hard CYP1A2 contraindications with fluvoxamine and ciprofloxacin. Teach nurses to flag new antibiotics and psych medications on patients with Zanaflex on the MAR. A single urgent care visit that adds cipro for dysuria can convert a stable spasticity regimen into an orthostatic collapse within forty-eight hours because exposure rises not by twenty percent but by multiples when 1A2 is blocked.

Capsule versus tablet is not a pharmacist pedantry issue. Bridging studies for FDA approval demonstrated different food effects and peak concentrations between dosage forms at the same milligram strength. A patient stable on 4 mg capsule TID who receives 4 mg tablet TID after insurance change may report loss of efficacy or new sedation depending on timing with meals. Retitration from 2 mg bedtime is the labeled conservative approach; skipping retitration is how real patients experience 'the generic stopped working' or 'I cannot stay awake since the pharmacy switched.' Document dosage form in the problem list alongside dose milligrams.

Wheelchair users with SCI may benefit from reduced adductor tone for transfers while needing enough extensor tone for stability-tizanidine is not a one-size-fits-all 'relax everything' drug. Goal-directed dosing with PT input beats automatic TID scheduling on discharge summaries.

MS patients on tizanidine for years still need CYP1A2 screening at every new prescription-stability does not eliminate interaction risk when urgent care adds antibiotics.

Spinal alpha-2 quieting, not a peripheral block

Tizanidine is an imidazoline derivative that acts as an agonist at alpha-2 adrenergic receptors in the central nervous system. The antispastic effect is primarily spinal: presynaptic alpha-2 activation on interneurons reduces release of glutamate and aspartate, which decreases polysynaptic excitation of alpha motor neurons.

That mechanism explains why you see improved Ashworth scores and patient global impression without the flaccid paralysis pattern of neuromuscular blockers. Reflex amplitude drops; voluntary strength at low doses is often preserved better than many residents expect from a 'muscle relaxant' label.

Card note: supraspinal alpha-2 agonism also produces sedation, dry mouth, and hypotension-classic clonidine-family physiology. Dose titration is usually limited by these effects before you max out antispastic benefit. Patients who feel 'drugged' at 2 mg at bedtime may still need that dose for nocturnal spasms; counsel about timing rather than reflexively stopping.

Tizanidine does not potentiate GABA-A receptors like baclofen. Combining tizanidine with baclofen, benzodiazepines, gabapentinoids, or opioids is not contraindicated pharmacodynamically, but sedation and fall risk stack fast. I mention gabapentin here because neuropathic pain and spasticity overlap in SCI and MS-polypharmacy is the norm, not the exception.

Animal models show increased primary afferent inhibition and reduced facilitation of spinal reflexes. In humans, electromyographic studies during spasticity trials confirm reduced stretch reflex activity at rest and during passive movement. You are not blocking acetylcholine at the neuromuscular junction; do not expect train-of-four changes.

Receptor reserve and downstream signaling mean small dose changes can produce nonlinear clinical effects in sensitive patients. That is one reason bedtime initiation at 2 mg is standard-you are probing central alpha-2 sensitivity before committing to daytime doses that could impair driving or therapy participation.

Clonidine and tizanidine share alpha-2 physiology but are not interchangeable in spasticity protocols. Clonidine has more prominent cardiovascular effects at antihypertensive doses and lacks the spasticity trial dataset tizanidine carries for MS and SCI.

Dantrolene acts peripherally on sarcoplasmic reticulum calcium release-it is the answer for malignant hyperthermia and a different side-effect profile (hepatotoxicity) than tizanidine. Mechanism questions on exams love that contrast.

Botulinum toxin chemodenervation treats focal spasticity; tizanidine treats more generalized tone. They complement rather than replace each other in comprehensive SCI programs.

Draw the spinal reflex arc for residents: interneuron alpha-2 agonism reduces glutamate release; baclofen hits GABA-B on the same sketch. Side-effect prediction follows-weakness versus hypotension and dry mouth.

CYP1A2 clearance and the capsule-tablet food split

Oral bioavailability averages about 40% but varies widely between patients. Peak plasma concentration occurs roughly one hour after dosing on an empty stomach, though the exact Tmax shifts with formulation and food.

The half-life is short-about 2.5 hours-so clinical effect tracks reasonably well with Cmax. Active metabolites contribute minimally. You are managing a drug where missed doses may allow spasticity rebound the same day, and extra doses stack hypotension risk quickly.

Hepatic metabolism via CYP1A2 is the dominant clearance route. Smokers induce CYP1A2 and may need higher doses to achieve the same effect; smoking cessation can raise levels unexpectedly. Oral contraceptives can inhibit CYP1A2 modestly-less dramatic than fluvoxamine, but worth noting when blood pressure drifts after starting combined hormonal therapy.

Here is the formulation issue that catches people: Zanaflex capsules taken with food can increase Cmax by up to two-fold compared with fasting administration. Tablets show a different food interaction magnitude. FDA explicitly states capsules and tablets are not bioequivalent on a mg-for-mg basis. When a pharmacy switches dosage form during a generic substitution, retitrate from a low dose.

Protein binding is about 30%. Volume of distribution is not clinically central here; CNS penetration is the point. Renal elimination of metabolites matters mainly when you are thinking about accumulation in severe renal failure-hepatic clearance is still the main story.

Because half-life is short, divided dosing (typically TID) matches pharmacokinetics better than once-daily regimens used in some other muscle relaxants. Extended-release formulations are not part of standard U.S. labeling-do not assume ER behavior from IR tablets.

Fluvoxamine can increase tizanidine AUC more than ten-fold in interaction studies-that is not a rounding error. It is why the interaction is contraindicated rather than 'space the doses.'

Ciprofloxacin is the quinolone you see most often in real charts. Levofloxacin and others may also inhibit CYP1A2 to varying degrees-when an MS patient needs antibiotics, choose agents that do not touch 1A2 when tizanidine must continue.

Caffeine and cruciferous vegetables subtly affect CYP1A2 in theory; the clinical wins there are small compared with fluvoxamine or cipro. Focus teaching on hard contraindications first.

Peak-trough fluctuation is large with TID dosing. If hypotension tracks with peaks, splitting the same total daily dose into more frequent smaller doses sometimes smooths blood pressure while preserving antispastic effect-empiric but useful.

Explain capsule food effect plainly: stomach contents change peak level. Heavy breakfast can double Cmax for capsules-pick fed or fasted and stay consistent through generic switches.

Smoking induces CYP1A2; quitting raises levels. Ask about tobacco at titration visits, not only at initiation.

Ashworth points that still leave transfers intact

Card note: registration trials in multiple sclerosis used Ashworth scale scores and clinician/patient global assessments over four to eight weeks. Tizanidine at total daily doses of 8-12 mg (divided) beat placebo on muscle tone endpoints with statistical significance, though effect sizes are modest-this is symptomatic therapy, not disease modification.

Card note: onset of action is typically one to two hours after a dose, aligning with peak plasma levels. Patients often dose before physical therapy or before bedtime when nocturnal spasms disrupt sleep. If spasms cluster at night, prioritize evening dosing before pushing high daytime doses that cause somnolence.

Comparison trials and crossover studies against baclofen generally show similar antispastic efficacy at group level. Individual response differs: some patients fail baclofen due to weakness, others fail tizanidine due to hypotension or dry mouth. Trial-and-error with one agent at adequate dose and duration is reasonable before switching.

Spinal cord injury populations mirror MS data in broad strokes-reduced spasticity scores and improved comfort. Functional gains (faster transfers, easier catheterization, better sleep) matter more to patients than point changes on Ashworth. Ask targeted questions instead of relying on the scale alone.

Card note: tizanidine does not treat spasticity's underlying lesion. Disease progression, infection, bladder distention, and skin breakdown can all worsen spasticity acutely-always look for reversible triggers before blaming drug failure.

Evidence for long-term benefit assumes continued use. Abrupt discontinuation after chronic therapy can produce rebound hypertension and tachycardia (clonidine-like withdrawal). Plan tapers when stopping after weeks to months of regular dosing.

Functional outcomes-timed ten-meter walk, dressing independence, caregiver burden-often improve modestly even when Ashworth changes by only one point. Document baseline function so patients see progress the scale undercounts.

Stroke-related spasticity uses tizanidine off-label frequently. Trial data are thinner than MS/SCI, but mechanism and safety considerations transfer-watch hypotension in older stroke survivors on polypharmacy.

Placebo-controlled trials ran four to eight weeks; long-term open-label follow-up shows sustained benefit when tolerated. Loss of effect over years usually reflects disease progression or new noxious stimuli (UTI, pressure injury), not tachyphylaxis.

Night spasms waking a partner, inability to dress, pain from flexor tone-valid success measures beyond one-point Ashworth change.

Crossover designs comparing tizanidine and baclofen in MS often show patient preference splits: some tolerate dry mouth better than weakness, others the reverse. Run adequate trials of one agent-typically two to four weeks at target dose-before switching.

Card note: therapists sometimes report improved range of motion before patients subjectively notice change. Document PT notes when justifying continued therapy or dose increases to payers who only see diagnosis codes.

Spasticity itself fluctuates with nociceptive input-a full bladder, ingrown toenail, UTI, or pressure injury can spike tone overnight. Before declaring tizanidine failure at 24 mg daily, search for triggers common in SCI and MS populations. Conversely, improved seating, better bladder management, or infection treatment may allow dose reduction. Tizanidine treats symptomatic hypertonia; it does not remove the upper motor neuron lesion. Expectations anchored to Ashworth scores alone miss functional wins like uninterrupted sleep or easier catheterization.

Intrathecal baclofen pumps, botulinum toxin injections, and phenol neurolysis occupy escalating rungs on spasticity ladders when oral agents max out. Tizanidine oral therapy failing at 36 mg with unacceptable hypotension is not an indication to sneak higher off-label-it is an indication for referral. Some patients combine low-dose oral tizanidine at night with focal botulinum toxin for adductor spasm; polytherapy requires explicit goals per modality. Gabapentin co-prescription for neuropathic pain below the level of injury adds sedation without helping spasticity mechanism-audit sedating burden before adding a fourth CNS depressant.

From 2 mg bedtime toward a 36 mg daily stack

Start 2 mg at bedtime. Spasticity flares at night; sedation is less disruptive when the patient is already going to sleep. If tolerated after a few days, add 2 mg daytime doses and titrate by 2-4 mg per day at intervals of several days based on effect and blood pressure.

Usual effective range is 8-24 mg/day divided TID. FDA maximum is 36 mg/day; single doses above 16 mg were not studied. If someone is still spastic at 36 mg with acceptable vitals, the problem is probably wrong drug or need for intrathecal therapy-not 'just a little more tizanidine.'

When switching between capsule and tablet, restart titration at 2 mg bedtime. Do not continue the same milligram total because insurance changed the dosage form. Document the switch in the chart and tell the patient to expect a retitration week.

Hepatic impairment: use caution; severe hepatic disease may warrant avoidance because CYP metabolism is already compromised. There is no neat Child-Pugh table in labeling-clinical judgment and lower doses apply.

Renal impairment: no specific dose adjustment in mild-to-moderate disease, but hypotension risk rises in debilitated patients. Monitor orthostatics in SCI patients with autonomic dysreflexia history when starting or increasing dose.

Do not crush capsules for dysphagia without checking formulation science with pharmacy-altered absorption may spike Cmax. If swallowing is impossible, consider baclofen suspension or other routes rather than improvising with capsule contents.

Occupational therapists sometimes want peak antispastic effect during morning ADLs-schedule the morning dose sixty to ninety minutes before session start based on one-to-two-hour onset.

If blood pressure runs low at 24 mg/day but spasticity remains problematic, splitting into four doses or adding focal botulinum toxin may beat pushing to 36 mg where hypotension dominates.

Document formulation on every prescription renewal: 'tizanidine capsule 4 mg TID' versus tablet prevents pharmacy auto-substitution surprises.

Inpatient SCI rehab: start low while autonomic tone stabilizes. BP 90/60 at baseline may mean night-only dosing is the ceiling.

Maximum 36 mg/day comes from trial design, not physiologic ceiling-patients who need more should trigger intrathecal baclofen evaluation rather than off-label dose escalation without specialist input.

Fluvoxamine and cipro are stops, not monitors

Card note: contraindicated with strong CYP1A2 inhibitors: fluvoxamine, ciprofloxacin, and zileuton. Post-marketing reports describe profound hypotension, bradycardia, and syncope when tizanidine was combined with these agents. If your MS patient needs a quinolone, pick one that does not hammer CYP1A2-or choose a non-quinolone antibiotic.

Card note: moderate CYP1A2 inhibitors (cipro's cousins, some fluoroquinolones, amiodarone, cimetidine) require extreme caution even when not labeled contraindicated. When in doubt, check a interaction reference against CYP1A2, not just 'muscle relaxant' class lists.

Oral contraceptives may reduce tizanidine clearance modestly. Watch blood pressure when starting or changing hormonal therapy in someone stable on tizanidine.

Additive CNS depression with benzodiazepines, opioids, gabapentin, pregabalin, sleep aids, and alcohol. No single interaction checker captures fall risk-ask about sedating OTC antihistamines too.

Antihypertensives plus tizanidine can produce symptomatic orthostatic hypotension. This is pharmacodynamic stacking, not a CYP issue. Teach patients to rise slowly and report syncope.

Smoking induces CYP1A2; smoking cessation increases exposure. Retitration may be needed after quit attempts-nicotine replacement does not remove the enzyme induction overnight.

Medication reconciliation in the ED matters: a patient on tizanidine who receives fluvoxamine for anxiety or cipro for UTI can syncopize within a day. Build CYP1A2 into your interaction checklist template.

Zileuton, an leukotriene synthesis inhibitor, is another labeled contraindication-rare in practice but tested on boards.

Card note: verapamil and other antihypertensives are not CYP1A2 issues but add orthostatic hypotension-stand the patient up before discharge if you started both same visit.

EMR quick-list: fluvoxamine, ciprofloxacin, zileuton. Covering MS panels-scan new psych meds; fluvoxamine appears more than expected.

Hypotension and sedation hit before tone relief

Most common: somnolence, dizziness, dry mouth, and weakness. Dry mouth is dose-related and bothersome enough that some patients prefer baclofen despite different side effects.

Hypotension and bradycardia are mechanism-based. Measure orthostatic vitals during titration in elderly patients, SCI patients with autonomic instability, and anyone on antihypertensives.

Hepatic transaminase elevations occur in a small fraction of patients-labeling recommends periodic LFT monitoring, especially in the first six months. Discontinue if persistent elevations exceed three times ULN or if jaundice appears.

Hallucinations and psychosis are rare but reported at higher doses. In MS, distinguish drug effect from disease-related cognitive changes by tying symptoms to dose changes.

Card note: withdrawal after chronic use: rebound hypertension, tachycardia, and increased spasticity if stopped abruptly. Taper over one to two weeks when discontinuing after regular use.

Card note: do not confuse tizanidine with tiZANidine look-alike/sound-alike errors involving clonidine or other alpha agonists-pediatric clonidine overdoses and adult tizanidine hypotension both land in emergency departments; verify the bottle.

Card note: lFT monitoring every three to six months in the first year catches asymptomatic transaminase rises. Most normalize with dose reduction or discontinuation.

Fatigue mistaken for MS relapse sometimes tracks with excessive tizanidine sedation-trial dose reduction before MRI.

Syncope workup in tizanidine patients should include orthostatics, ECG, and med list for new CYP1A2 inhibitors before attributing to autonomic MS.

Dry mouth worsens dental and speech issues in bulbar MS-sugar-free gum and dental follow-up are real interventions.

Hepatic caution and the renal accumulation case

Pregnancy: limited human data; use only if benefit clearly outweighs risk. Spasticity management in pregnancy may require PT, positioning, and non-pharmacologic measures first.

Lactation: unknown excretion in breast milk; consider alternative antispastic strategies in nursing mothers.

Pediatrics: not FDA-approved for spasticity in children, though off-label use occurs in cerebral palsy programs. Pediatric specialists often prefer baclofen or botulinum toxin for focal spasticity; if tizanidine is used off-label, start lower and monitor blood pressure.

Geriatrics: hypotension and falls dominate risk. Beers Criteria flags skeletal muscle relaxants for sedating older adults-if you must use tizanidine, use the lowest dose for the shortest time and reconcile sedating polypharmacy aggressively.

Hepatic impairment: reduce dose or avoid in severe disease; metabolism is hepatic.

Renal impairment: no labeled adjustment, but debilitated patients with reduced clearance of hypotension tolerance need slower titration.

Autonomic dysreflexia in SCI above T6 can mimic hypotension from tizanidine-know baseline BP and trigger history before blaming the drug.

Women on combined oral contraceptives may see slightly higher levels-watch dizziness after starting OCPs in stable tizanidine users.

Workers who operate heavy machinery need clear guidance on first daytime dose trials-document fitness-to-drive conversations.

Card note: sCI patients with recurrent UTIs get quinolones often-build CYP1A2 contraindication into UTI order comments when tizanidine is home med.

Form switches, night-only maps, and fall risk

Tell patients tizanidine may make them dizzy, especially when standing up quickly. They should not drive until they know how daytime doses affect them-many start with bedtime-only dosing for that reason.

If they take the capsule form, pick either always-with-food or always-without-food and stick to it. Switching breakfast patterns changes drug levels.

Hand them a med list card that says CYP1A2 interaction risk. Urgent care prescribers who do not know they take tizanidine are how cipro disasters happen.

Warn against stopping suddenly after months of daily use-rebound blood pressure and spasticity flare are real.

For MS and SCI clinics, coordinate with PT: dose before therapy if spasticity limits range of motion; avoid peak sedation during driving evaluations or bowel program training.

Card note: when spasticity persists despite 24-36 mg/day, the conversation is escalation (intrathecal baclofen, botulinum toxin, phenol blocks)-not endless dose creep.

Give a wallet card listing contraindicated drugs (fluvoxamine, ciprofloxacin, zileuton) for urgent care visits.

Teach caregivers to recognize oversedation and orthostatic falls-SCI and MS patients may not feel lightheaded until they are on the floor.

Card note: if pharmacy switches from capsule to tablet, schedule a follow-up call within one week to retitrate-not at the six-month visit.

Home BP log during titration in SCI and elderly MS prevents guessing orthostatic versus relapse symptoms.

Provide a one-page med list card listing contraindicated antibiotics and antidepressants (fluvoxamine, ciprofloxacin). Urgent care visits are where interactions happen.

If generic switch changes appearance of capsule or tablet, treat it like a new drug start for one week-call patient on day three and day seven for sedation and BP symptoms.

Liver enzyme monitoring in the first six months catches rare asymptomatic transaminase elevations. Most resolve with dose reduction or discontinuation. Do not ignore persistent three-fold ULN elevations hoping spasticity control justifies continued exposure-switch class to baclofen or escalate procedural options. Dry mouth contributes to dental disease and speech fatigue in MS bulbar symptoms; dental referrals and saliva substitutes belong in long-term spasticity care plans, not only anticholinergic discussions for other drugs.

Keep the 36 mg day and the 1A2 list

Tizanidine is a central alpha-2 agonist that reduces spasticity in MS and SCI by dampening spinal reflex hyperexcitability. It works within hours, clears via CYP1A2, and is limited by sedation and hypotension.

Before adding any new medication to a tizanidine patient, screen for CYP1A2 inhibitors-fluvoxamine and ciprofloxacin are contraindicated. Capsules and tablets are not interchangeable; retitrate after formulation changes.

Match dosing to function: bedtime for nocturnal spasms, divided doses for daytime tone, stop and taper thoughtfully rather than abandoning abruptly after chronic use.

Card note: run CYP1A2 interaction checks on every new prescription for spasticity patients-the contraindications are memorable because they prevent syncope, not because they are obscure trivia.

Capsule-with-food versus fasting consistency and formulation retitration belong in the same safety conversation as dose milligrams.

On call: tizanidine plus cipro or fluvoxamine can syncopize within days. Capsule versus tablet is not cosmetic. Balance tone relief against sedation and pressure-not zero Ashworth.

Ashworth scale improvement of one point may correspond to major functional gains in dressing or sleep-set patient-centered endpoints, not only reflex scores.

Card note: teaching pearl for boards and bedside: tizanidine is to spasticity what clonidine is to blood pressure pharmacology-same receptor family, different primary indication, shared hypotension risk, and hard CYP1A2 interaction contraindications that are non-negotiable in practice.